Literature DB >> 22531135

Resveratrol and piperine enhance radiosensitivity of tumor cells.

Jean Kyoung Tak1, Jun Ho Lee, Jeen-Woo Park.   

Abstract

The use of ionizing radiation (IR) is essential for treating many human cancers. However, radioresistance markedly impairs the efficacy of tumor radiotherapy. IR enhances the production of reactive oxygen species (ROS) in a variety of cells which are determinant components in the induction of apoptosis. Much interest has developed to augment the effect of radiation in tumors by combining it with radiosensitizers to improve the therapeutic ratio. In the current study, the radiosensitizing effects of resveratrol and piperine on cancer cells were evaluated. Cancer cell lines treated with these natural products exhibited significantly augmented IR-induced apoptosis and loss of mitochondrial membrane potential, presumably through enhanced ROS generation. Applying natural products as sensitizers for IR-induced apoptotic cell death offers a promising therapeutic approach to treat cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22531135     DOI: 10.5483/bmbrep.2012.45.4.242

Source DB:  PubMed          Journal:  BMB Rep        ISSN: 1976-6696            Impact factor:   4.778


  17 in total

1.  Combined effects of resveratrol and radiation in GH3 and TtT/GF pituitary adenoma cells.

Authors:  B Voellger; N Waldt; Rosita Rupa; E Kirches; O Melhem; H-J Ochel; C Mawrin; R Firsching
Journal:  J Neurooncol       Date:  2018-06-05       Impact factor: 4.130

Review 2.  Resveratrol-based combinatorial strategies for cancer management.

Authors:  Chandra K Singh; Jasmine George; Nihal Ahmad
Journal:  Ann N Y Acad Sci       Date:  2013-07       Impact factor: 5.691

Review 3.  Resveratrol: A potential challenger against gastric cancer.

Authors:  Aida Zulueta; Anna Caretti; Paola Signorelli; Riccardo Ghidoni
Journal:  World J Gastroenterol       Date:  2015-10-07       Impact factor: 5.742

4.  Piperine potentiates the antidepressant-like effect of trans-resveratrol: involvement of monoaminergic system.

Authors:  Wu Huang; Zhuoyou Chen; Qiandong Wang; Mengmeng Lin; Shujuan Wu; Qizhi Yan; Fan Wu; Xuefeng Yu; Xupei Xie; Gaowen Li; Ying Xu; Jianchun Pan
Journal:  Metab Brain Dis       Date:  2013-08-14       Impact factor: 3.584

Review 5.  Molecular mechanisms and cardiovascular implications of cancer therapy-induced senescence.

Authors:  Ibrahim Y Abdelgawad; Karim T Sadak; Diana W Lone; Mohamed S Dabour; Laura J Niedernhofer; Beshay N Zordoky
Journal:  Pharmacol Ther       Date:  2020-12-01       Impact factor: 12.310

6.  Apoptosis induction of human bladder cancer cells by sanguinarine through reactive oxygen species-mediated up-regulation of early growth response gene-1.

Authors:  Min Ho Han; Cheol Park; Cheng-Yun Jin; Gi-Young Kim; Young-Chae Chang; Sung-Kwon Moon; Wun-Jae Kim; Yung Hyun Choi
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

7.  Apoptosis induction of human prostate carcinoma DU145 cells by diallyl disulfide via modulation of JNK and PI3K/AKT signaling pathways.

Authors:  Dong Yeok Shin; Gi-Young Kim; Jun Hyuk Lee; Byung Tae Choi; Young Hyun Yoo; Yung Hyun Choi
Journal:  Int J Mol Sci       Date:  2012-11-02       Impact factor: 5.923

8.  Targeted intracellular delivery of resveratrol to glioblastoma cells using apolipoprotein E-containing reconstituted HDL as a nanovehicle.

Authors:  Sea H Kim; Birendra Babu Adhikari; Siobanth Cruz; Michael P Schramm; Joe A Vinson; Vasanthy Narayanaswami
Journal:  PLoS One       Date:  2015-08-10       Impact factor: 3.240

9.  Resveratrol decreases B-cell lymphoma-2 expression and viability in GH3 pituitary adenoma cells of the rat.

Authors:  Benjamin Voellger; Elmar Kirches; Annette Wilisch-Neumann; Andreas Weise; Jorge Humberto Tapia-Perez; Rosita Rupa; Christian Mawrin; Raimund Firsching
Journal:  Onco Targets Ther       Date:  2013-09-16       Impact factor: 4.147

Review 10.  Enhancement of radiosensitization by metal-based nanoparticles in cancer radiation therapy.

Authors:  Xiang-Yu Su; Pei-Dang Liu; Hao Wu; Ning Gu
Journal:  Cancer Biol Med       Date:  2014-06       Impact factor: 4.248

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.